Ann-marie M. Quigley
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Impact of peptide receptor radionuclide therapy (PRRT) on the quality of life in patients with neuroendocrine tumours.
Journal: Journal of neuroendocrinology
Published: March 24, 2026
Efficiency and Sustainability in the Skin Cancer Excision Pathway: Life Cycle Assessment and Process Map.
Journal: JMIR dermatology
Published: December 22, 2025
68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours.
Journal: Endocrine oncology (Bristol, England)
Published: June 07, 2025
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.
Journal: Endocrine oncology (Bristol, England)
Published: February 22, 2025
Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.
Journal: Endocrine oncology (Bristol, England)
Published: December 22, 2024
Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled.
Journal: Seminars in nuclear medicine
Published: March 08, 2024
Dosing lutetium Lu 177-dotatate for a hemodialysis patient.
Journal: Hemodialysis international. International Symposium on Home Hemodialysis
Published: October 12, 2023
Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.
Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.
Journal: Clinical nuclear medicine
Published: May 11, 2023
Comparison of different technetium-99m-labelled bone tracers for imaging cardiac amyloidosis.
Journal: European journal of preventive cardiology
Published: September 01, 2022
Single centre retrospective review of outcome of 177 Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors.
Journal: Journal of neuroendocrinology
Published: June 04, 2022
The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
Journal: Clinical nuclear medicine
Published: December 07, 2021
177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 26, 2020
Last Updated: 09/26/2026